- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05201066
Roll-over-studie för patienter som har genomfört en tidigare Novartis-sponsrad Sabatolimab-studie (MBG453) och som bedöms av utredaren att dra nytta av fortsatt behandling med Sabatolimab.
En öppen, multicenter, roll-over-studie för patienter som har genomfört en tidigare Novartis-sponsrad Sabatolimab-studie (MBG453) och som av utredaren bedöms dra nytta av fortsatt behandling med Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Studieöversikt
Status
Detaljerad beskrivning
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Novartis Investigative Site
-
-
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- Novartis Investigative Site
-
-
-
-
-
Toulouse, Frankrike, 31059
- Novartis Investigative Site
-
-
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
-
-
-
Alexandroupoli, Grekland, 681 00
- Novartis Investigative Site
-
Pátrai, Grekland, 265 04
- Novartis Investigative Site
-
-
-
-
BS
-
Brescia, BS, Italien, 25123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Italien, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italien, 16132
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italien, 20162
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00133
- Novartis Investigative Site
-
-
-
-
-
Fukushima, Japan, 9601295
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Novartis Investigative Site
-
-
-
-
-
Tianjin, Kina, 300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Novartis Investigative Site
-
-
-
-
-
Zurich, Schweiz, 8091
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08036
- Novartis Investigative Site
-
Madrid, Spanien, 28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Novartis Investigative Site
-
-
-
-
-
Prague, Tjeckien, 128 08
- Novartis Investigative Site
-
-
-
-
-
Izmir, Turkiet (Türkiye), 35100
- Novartis Investigative Site
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
Andra namn:
Solution for subcutaneous injection or intravenous infusion |
|
Experimentell: sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
Andra namn:
Solution for intravenous infusion |
|
Experimentell: sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
Andra namn:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
Experimentell: sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
Andra namn:
Solution for intravenous infusion Solution for intravenous infusion
Andra namn:
|
|
Experimentell: sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
Andra namn:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
Experimentell: sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: 5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
Tidsram: 5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Duration of exposure to sabatolimab
Tidsram: 5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Leukemi, myeloid
- Myelodysplastiska-myeloproliferativa sjukdomar
- Benmärgssjukdomar
- Leukemi
- Patologiska tillstånd, tecken och symtom
- Hemiska och lymfsjukdomar
- Leukemi, myelomonocytisk, kronisk
- Myelodysplastiska syndrom
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Nukleinsyror, nukleotider och nukleosider
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- AZA -föreningar
- Nukleosider
- Ribonukleosider
- Decitabin
- Azacitidin
- venetoklax
- Decitabine och cedazuridin läkemedelskombination
- spartalizumab
- sabatolimab
Andra studie-ID-nummer
- CMBG453B12206B
- 2021-004422-30 (EudraCT-nummer)
- 2024-515281-14-00 (Registeridentifierare: EU CTIS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .